Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal despite its known efficacy in reducing recurrence and mortality. This study aims to investigate factors associated with non-adherence and inform the development of interventions to support women and promote adherence. A questionnaire survey to measure level of adherence, side effects experienced, beliefs about medicine, support received and socio-demographic details was sent to 292 women 2-4 years post breast cancer diagnosis. Differences between non-adherers and adherers to AET were explored, and factors associated with intentional and unintentional non-adherence are reported. Approximately one quarter of respondents, 46 (22%), were non-adherers, comprising 29 (14%) intentional non-adherers and 17 (8%) unintentional non-adherers.
as prescribed, yet studies report suboptimal adherence, with almost half of all women not completing the currently recommended 5-year course of treatment (Makubate, Donnan, Dewar, Thompson, & McCowan, 2013; McCowan et al., 2008) . A systematic review of studies in clinical practice found persistence over 5 years as between 31% and 73% (Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012) . Other reviews report that up to 50% of women either do not take the correct dosage at the prescribed frequency or discontinue therapy (Banning, 2012; Chlebowski & Geller, 2006; Gotay & Dunn, 2011; Hadji, 2010) . Low adherence to AET is associated with reduced quality-adjusted life years, increased medical costs and a 30% increased risk of mortality due to recurrence (Makubate et al., 2013; McCowan et al., 2008; Murphy et al., 2012) . It has been calculated that in the UK setting, encouraging women to take their full course of AET could save 400-500 lives every year and bring substantial benefit to health service budgets by potentially freeing up nearly £30 million per year (Hershman et al., 2011; Makubate et al., 2013) . High adherence to AET would also benefit both patients and health care services internationally (Delea et al., 2006; Glasziou & Haas, 1994; Yang et al., 2010) .
Factors previously associated with low adherence to medication include side effects, anxiety and depression, poor patient-clinician relationships, forgetfulness, medication concerns, limited belief in the efficacy of the medication and demographical factors (Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004; Khan et al., 2009; Wickersham, Happ, & Bender, 2012; Wouter et al., 2013) . Horne and Weinman (1999) developed a useful conceptual model for understanding patients' perspectives and beliefs on prescribed medicines (Horne & Weinman, 1999) . They also distinguished between two broad categories of non-adherers: intentional and unintentional nonadherers. Unintentional non-adherence occurs when a patient finds it difficult to schedule, administer or remember the treatment, or lack capacity to self-manage the medication themselves (Horne et al., 2013) . Intentional non-adherence occurs when a patient consciously decides not to follow the recommendations. This is best understood in terms of perceptual factors (e.g. beliefs around the medication and preferences to avoid side effects) influencing motivation to start and continue with treatment (Aikens, Nease, Nau, Klinkman, & Schwenk, 2005; Clifford, Barber, & Horne, 2008) . How patients' beliefs about medication affect intentional and unintentional adherence has been explored in other disease groups (Clifford et al., 2008; Horne et al., 2013; Molloy, O'Carroll, & Ferguson, 2014) .
While previous evidence has reported on factors affecting nonadherence to AET, such as side effects, concerns around toxicity and psycho-social factors (Cahir et al., 2015; Hadji et al., 2013; Harrow et al., 2013; Van Liew, Christensen, & de Moor, 2014) , none have identified the extent to which behaviour is intentionally non-adherent or unintentionally non-adherent. However, characterisation by the different behaviours is important to inform the development of interventions to improve adherence. This study, therefore, aims to identify factors associated with non-adherence (both intentional and unintentional) to AET to inform interventions to support women, promote adherence and ultimately improve outcomes for women with breast cancer.
| METHODS

| Design
The study is a cross-sectional survey of a subgroup of participants in an existing cohort study.
| Recruitment
Women from the Joint Aches Cohort study (JACS) (Fenlon, Powers, Simmonds, Clough, & Addington-Hall, 2014) were invited to participate. The JACS study was set up in 2010 to explore the onset of joint pain following breast cancer treatment. All patients diagnosed with primary breast cancer within a set time frame were invited at surgery and prior to adjuvant treatment, to participate in a questionnaire study. A total of 543 women took part, representing 57% of the eligible cohort. Of these women, 292 had been prescribed AET and were invited to participate in this study, by a letter from the original study research team (Fenlon et al., 2014) . All had previously indicated consent to participate in future research.
Those who wished to take part were asked to complete and return a postal questionnaire which addressed their experiences and beliefs about AET. Postal questionnaires were sent out in July 2014, with a single reminder sent to non-responders after 3 weeks. Ethics approval was gained through Oxford Brookes University, supplementing NRES approval for the original cohort study.
| Questionnaire
The questionnaire comprised the following validated measures and additional questions to address areas of interest where no existing measures were available. The final questionnaire took approximately 20 min to complete.
The Beliefs about Medicine Questionnaire (BMQ) (Horne & Weinman, 1999 ) assesses individuals' specific beliefs and understanding of the medication they are taking as well as general attitudes to taking medicines (Horne & Weinman, 1999) . The measure comprises two sections, each divided into two subscales. The BMQ Specific comprises two 5-item subscales: the Specific Necessity subscale (i.e. beliefs about the necessity of taking that specific medication to remain healthy) and the Specific Concerns subscale (i.e. concerns about the negative effects of taking that specific medication). The BMQ General comprises two 4-item subscales: the General Harm subscale which assesses beliefs about medicines as harmful, addictive, poisons which should not be taken continuously and the General Overuse subscale which assesses beliefs that medicines are overused by doctors. For this study, the wordings of the items in the BMQSpecific section were modified, as advised by Horne et al. (1999) , to be more specific to women taking AET after breast cancer and to ensure face validity.
All items of the BMQ are rated on a 5-point Likert scale where 1 represents strongly agree and 5 represents strongly disagree. Scores obtained for the individual items are summed to give a total score for each subscale. A lower score equals a stronger belief. For example, a lower score on the Specific Necessity scale is a stronger belief in the necessity of taking the medication; a lower score on the Specific Concerns scale implies stronger belief of concerns about taking the medication (Horne, Weinman, Barber, Elliott, & Morgan, 2006; Horne et al., 2013) . Total scores for the Necessity and Concerns subscales range from 5 to 25 and total scores for the Harm and Overuse subscales range from 4 to 20. The two sections of the BMQ can be used in combination or separately, but are reported separately in this article. Psychometric evaluation of the BMQ in this population has been tested (Brett et al., 2016) .
The Medical Adherence Report Scale (Thompson, Kulkami, & Sergejew, 2000) MARS and the additional questions were combined to overcome issues of underreporting of non-adherence (Hamilton, 2003; Molloy, Mersserl-Burgy et al., 2014; Sewitch et al., 2003) . Items 1 and 6 of the MARS refer to unintentional non-adherence, and items 2-5 refer to intentional non-adherence (Molloy, O'Carroll et al., 2014) . Singleitem questions about adherence have been shown to correlate with the MARS in identifying the nature of adherence (Hamilton, 2003) .
Using the MARS and the four independent questions about level of adherence, the sample was divided into three groups. Two nonadherer groups (unintentional non-adherers and intentional nonadherers) and adherers:
1. Adherers (Still taking AET, never had a break from AET, never considered stopping taking AET, taking AET daily in the last week, score ≥4 on all MARS items).
2.
Intentional non-adherence (have stopped taking AET permanently, have stopped taking AET temporarily, have taken a break from AET, score ≤3 on MARS statements "I change my dose of my hormone treatment," "I stop taking my hormone treatment for a while," "I decide to skip one of my treatments," "I take the treatment less than prescribed." 3. Unintentional non-adherence (Intending to adhere: Still taking AET, never had a break from AET, never considered stopping taking AET.
But not taking as prescribed: not taken daily, score ≤3 on MARS statements "I forget to take my AET, and I don't order my prescription on time)." Additional questions were included on side effects experienced and their impact on daily life, and whether AET was discussed at hospital follow-up appointments or with the general practitioner (GP) in primary care. Demographical data were collected, including age, marital status, employment status, education and ethnic group.
| Statistical analysis
Data were analysed using spss version 21 (IBM Corporation, New York, USA). Descriptive statistics were performed for the sample as a whole. T-tests were conducted to explore differences between adherers and non-adherers for the BMQ. Factors significantly associated with intentional and unintentional non-adherence were explored using Pearson chi-square = d test of independence, with p < .05 as the chosen level of significance, and using adherers as the comparison group. A final logistic regression was performed to identify predictors of non-adherence, comparing all non-adherers vs. all adherers.
| RESULTS
Two hundred and eleven completed questionnaires were returned, a response rate of 73%. The majority of women (165, 78%) were adherers to AET, although 20 (9%) had contemplated stopping.
Approximately one quarter of respondents, 46 (22%), were nonadherers, comprising 29 (14%) intentional non-adherers and 17 (8%) unintentional non-adherers.
Demographical and clinical characteristics of the sample are summarised in Table 1 .
| Side effects of AET and the impact on adherence
A total of 127 (60%) women reported side effects, with a significantly higher proportion of non-adherers (41/49, 84%) than adherers 86/165 (52%) reporting them (p < .001). The most common side effects reported were hot flushes, joint ache or pain, weight gain, fatigue and tiredness, and depression/low mood. Other side effects reported were vaginal dryness and vaginal discharge, lack of concentration, low esteem and low confidence, and low libido. Of those who reported a side effect, 83% (105/127) stated this had a moderate to high impact on their lives. Table 2 reports the total number reporting side effects, the proportion reporting the most common side effects, and the proportion reporting that these side effects had a moderate to high impact on their lives.
A significant association between "having side effects" and "intentional non-adherence" was reported (χ 2 = 0.178, 1 df, p < .03). The relationship was stronger between "having side effects with moderate to high impact on life" and "intentional non-adherence" (χ 2 = 0.290, 1 df, p < .01). No significant association between having side effects and unintentional non-adherence (χ 2 = 0.038 (1 df), p = .962) was found. (15) 18 (11) 13 (28) 4 (14) 9 (53) 51-64 years 80 (38) 61 (37) 19 (41) 15 (52) 4 (24) ≥65 years 87 (41) 73 (44) 14 (30) 10 (34) 4 (24) Not provided 13 (6) 13 (6) Marital status Married 167 (79) 130 (79) 37 (80) 23 (79) 14 (82) Divorced 21 (10) 18 (11) 3 (7) 3 (10) Widowed 13 (6) 11 (7) 2 (4) 2 (7) Single 10 (5) 6 (4) 4 (9) 1 (4) 3 (17) Employment status Retired 105 (50) 88 (53) 17 (37) 13 (45) 4 (23) Paid work 87 (41) 64 (39) 23 (14) 12 (41) 11 (65) Sick leave/unable to work 9 (4) 6 (4) 3 (7) 2 (7) 1 (6) Table 3 
| Beliefs about medicine and impact on adherence
| General beliefs of taking medication and impact on adherence
| Support from health professionals and impact on adherence
Of those still attending hospital clinic appointments, 51% (92/179) reported AET was always discussed, 34% (60/179) reported AET T A B L E 2 Number and proportion reporting side effects and moderate or high impact of side effects, for total sample and for adherers and non-adherers 6.69 (6.47-6.91)*** C = concerns, N = necessity; Likert scale: 1 = strongly agree; 2 = agree; 3 = uncertain; 4 = disagree; 5 = strongly disagree. *p < .05, **p < .001, ***p < .0001.
was sometimes discussed and 16% (29/179) reported AET was never discussed. Forty-one per cent (86/210) of the total sample reported having discussed AET with their GP. No significant associations were found between response to "discussed at hospital appointments" or "discussed with GP" and non-adherence.
| Demographical factors and adherence
Younger age (<65 years) (χ 2 = 0.283 (df 1), p = .01), higher education (completed college education and above) (χ 2 = 0.140 (df 1), p = .046) and in-paid employment (χ 2 = 0.174 (df 1), p = .031) were significantly associated with unintentional non-adherence.
No significant associations between demographical factors and intentional non-adherence were found.
| Multivariate analysis of factors predicting nonadherence
Logistic regression was performed to identify predictors of nonadherence to AET. The factors included were as follows: BMQ Necessity (continuous total scores), BMQ Concerns (continuous total scores), BMQ Harm (continuous total scores) and BMQ Overuse (continuous total scores), side effects (yes/no), age (in years), education (post-secondary/secondary or less) and employment status (in-paid employment/not in-paid employment) (Table 5 ).
Only two variables were found to be significant predictors of non-adherence: side effects (OR 4.383, p < .04) and BMQ Concerns (OR: 1.181, CI 1.033-1.350, p < .015).
Eliminating non-significant factors from the model had little effect on the model. The sample size was not large enough to allow separate predictors of intentional and unintentional non-adherence to be calculated.
| DISCUSSION
This study explored differences between non-adherers and adherers to AET in women with breast cancer, with regard to medication beliefs, side effects and support provided and reports factors associated with intentional and unintentional non-adherence. The strongest predictors of non-adherence in the sample as a whole were the presence of side effects and having significant concerns about taking AET.
Intentional non-adherence was significantly associated with concerns about taking AET, side effects and lower belief in the necessity of taking AET. Unintentional non-adherence was associated with younger age (<65), in-paid employment and a higher level of education.
Adjuvant endocrine therapies are known to have a significant side effect profile which can adversely affect quality of life and have previously been cited as barriers to continuing with treatment (Cella & Fallowfield, 2008; Fenlon, Corner, & Haviland, 2009; Harrow et al., 2013; Morgan & Fenlon, 2013) . In our study, nearly two thirds of women reported side effects they attributed to AET, with most reporting a moderate to high impact on their daily lives. The association between side effects and intentional non-adherence was calculated using the total number of women reporting any side effects. The relationship with intentional nonadherence was stronger for women whose side effects had a moderate or high impact on their lives. With an increasing number of women surviving breast cancer, and increasing periods of time on AET now being recommended (Gray, 2013) , there is a pressing need for effective interventions to manage symptoms for this patient group. Side effects can sometimes be managed by switching to another preparation or to another agent, if appropriate to women's menopausal status. Pharmacological treatment may alleviate the symptoms of AET, including small doses of the selective serotonin reuptake inhibitor (SSRI) anti-depressants, such as venlafaxine and citalopram (Archer et al., 2009 ), anti-epileptic drugs (gabapentin) (Pandya, Morrow, Roscoe, & Hickok, 2005) and progesterones (Bertelli et al., 2002) .
Some women may prefer use of complementary therapies, although there is limited evidence of their effectiveness (Chiu, Shyu, Chang, & Tsai, 2016) .
The influence of concerns with taking AET on non-adherence have also been explored in other studies (Grunfeld, Hunter, Sikka, & Mittal, 2005; Stanton, Petrie, & Partridge, 2014; Wouter et al., 2013) .
Alongside the relatively well-known side effects that women can experience, such concerns may include fear of long-term risks of taking AET, such as deep venous thrombosis, pulmonary embolism or endometrial cancer from tamoxifen and osteoporotic fracture from AIs.
Furthermore, women may be reluctant to take additional "toxic" medication following surgery, chemotherapy and radiotherapy particularly if they lack confidence in the value of the medication.
Factors associated with unintentional non-adherence have not previously been identified in this population. A review of the evidence exploring common factors causing therapeutic non-compliance reported that younger working women are more likely to be poor adherers due to juggling work and family (Jin, Sklar, Vernon, & Chuen Li, 2008) . This may relate to women in this study too, although further investigation is needed.
The results of this study also support studies that have explored non-adherence to a broad spectrum of medications. A meta-synthesis of qualitative studies looking at adherence to medications, in general, reported that the main reason people do not adhere is because of concerns about the medicines themselves, such as worries of dependence, tolerance and addiction, the potential harm from taking medicines on a long-term basis and the possibility that medicine masks other symptoms (Pound et al., 2005) . Furthermore, a meta-analysis of studies which have used the necessity-concerns framework (Horne et al., 2013) found that higher adherence was associated with fewer concerns about treatment and stronger perceptions of necessity of treatment.
While results of this study supports previous qualitative studies that have explored themes relating to non-adherence to AET (Cahir et al., 2015; Flanagan, Winters, Habin, & Cahavelly, 2012; Harrow et al., 2013; Pellegrini et al., 2010; Vergbrugghe et al., 2015; Wouter et al., 2013) , the study adds to the literature by dividing non-adherers into intentional and unintentional non-adherence categories and by identifying the most significant factors associated with these categories. Strategies to improve adherence will have to recognise that implicit unconscious processes (such as unintentional non-adherence) and the more explicit conscious (intentional) processes exist (Strack & Deutsch, 2004) . It may prove useful for health professionals to distinguish between those who are intentional non-adherers and those who are unintentional nonadherers to tailor support and interventions.
While fostering tailored interventions that address non-adherence to AET are needed, further research is also needed around who is best placed to deliver these interventions. Currently, there is no formal monitoring of adherence or standardised protocol for discussing AET, either in hospital or community (Harrow et al., 2013) . Alongside these more practical interventions, novel ways in which health professionals could improve adherence through e-health interventions such as tailoring of messages through smart phones and tablets as a method of developing communication to influence specific health-related behaviours have been suggested (Dayer, Heldenbrand, Anderson, Gubbins, & Martin, 2013) . The evidence to date suggests that these tailored health messages can improve medical adherence (Mosa, Yoo, & Sheets, 2012) .
Limitations of this study include those common to postal surveys, including the potential for non-response bias and accuracy of selfreport. Participants are a self-selected sample, who had previously taken part in the JACS study. Furthermore, the sample size of nonadherers was too small to perform logistic regression separately for the intentional and unintentional non-adherers. However, the strengths include a good response rate providing a sufficient sample size to conduct a range of analyses. Association with comorbidities was not calculated. Eighty-three per cent of women reported having "other health conditions," but the data presented a diverse range of "other health conditions" and the severity of these comorbidities and whether medication was taken for these conditions was not reported. Future studies should explore the impact of comorbidities and polypharmacy on patients' lives and the extent to which these groups adhere to AET.
| CONCLUSIONS
This study has highlighted factors that influence intentional and unintentional non-adherence in women taking AETs following treatment for breast cancer and points to the need for interventions to support and monitor these women throughout their 5-10 years of AET. Future development of interventions to improve adherence to medication would benefit from paying particular attention to both intentional and unintentional aspects of non-adherence; interventions both to manage the side effect profile of AET and to modify particular medication-based beliefs seem especially relevant behaviour change strategies for this population. Novel approaches to improve adherence to AET through GP practices, community pharmacists or via e-health interventions may be useful. As increasing numbers of women are diagnosed with breast cancer, it is essential we optimise the management of women prescribed AET and find strategies which help women persist with therapy in order to reduce recurrence of disease and mortality.
